Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Rashi Ojha

Rashi Ojha is an MD candidate at David Geffen School of Medicine at UCLA.

Articles by Rashi Ojha

A Brainier Approach to ESG Investing

ByErin Smith,Rashi Ojha,Andrew W. Lo, PhD,Jeffrey L. Cummings, MD, ScD,William Hynes, DPhil,Harris A. Eyre, MD, PhD

March 26th 2021

Devoting funds to better benefit brain health could improve society as a whole.

Smart Growth: the Case for Measuring Brain Capital

ByAnika Sinha,Rashi Ojha,Erin Smith,William Hynes, DPhil,Cara Altimus, PhD,Sandra Bond Chapman, PhD,Ian Robertson, PhD,Husseini K. Manji, MD,Rym Ayadi, PhD,Harris A. Eyre, MD, PhD

February 18th 2021

Brain health disorders cost the global economy more than $3 trillion per year in lost productivity. What can we do about it?

Latest Updated Articles

Smart Growth: the Case for Measuring Brain Capital
Published: February 18th 2021 | Updated:

Trending on Psychiatric Times

Closing the Gap in Schizophrenia Care: Insights From the INTEGRATE Guidelines

The Importance of Guidelines

Turning Despair into Joy in Music, Psychiatry, and Society

Fostering Resiliency in Mental Health Professionals: A Strengths-Based, Trauma-Informed Framework

© 2025 MJH Life Sciences^®

All rights reserved.